Congenital syphilis: Difference between revisions
From IDWiki
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
(→) |
||
Line 1: | Line 1: | ||
== |
==Background== |
||
=== |
===Epidemiology=== |
||
* Rare, with about 20 per 100,000 live births in the US |
|||
* Greatest risk to child is with untreated primary maternal syphilis |
|||
*Rare, with about 20 per 100,000 live births in the US |
|||
=== Pathophysiology === |
|||
*Greatest risk to child is with untreated primary maternal syphilis |
|||
* Transplacental transmission while bacteremic |
|||
* Can be transmitted during delivery, as well |
|||
===Pathophysiology=== |
|||
== Clinical Manifestations == |
|||
* Mothers typically have had no prenatal care |
|||
* To the fetus, can cause [[Causes::spontaneous abortion]] (40% in untreated primary syphilis), [[Causes::preterm delivery]], [[Causes::polyhydramnios]], [[Causes::intra-uterine growth restriction]], [[Causes::hydrops fetalis]], or [[Causes::intra-uterine fetal demise]] |
|||
* At birth, two thirds of affected neonates are asymptomatic, with disease developing over the following 6 weeks |
|||
* Early disease, within the first two years, includes: |
|||
** [[Causes::Rhinitis]] (called [[Causes::snuffles]], often bloody and copious), [[Causes::desquamating rash]], [[Causes::hepatosplenomegaly]], [[Causes::lymphadenopathy]], and skeletal abnormalities |
|||
** Also: [[Causes::condyloma lata]], [[Causes::vesicular rash]] or [[Causes::bullous rash]], [[Causes::periostitis]], [[Causes::hydrops]], [[Causes::thrombocytopenia]], [[Causes::hepatitis]], [[Causes::jaundice]], or [[Causes::glomerulonephritis]] |
|||
** About 20% involve the CNS |
|||
* Late disease, after the first two years, includes: |
|||
** [[Causes::Sensorineural hearing loss]], [[Causes::intellectual impairment]], [[Causes::saddle nose deformity]], [[Causes::frontal bossing]], jaw, dental, and palatal abnormalities including [[Causes::Hutchison teeth]], [[Causes::saber tibia]], [[Causes::short stature]], and [[Causes::keratitis]] |
|||
*Transplacental transmission while bacteremic |
|||
== Diagnosis == |
|||
*Can be transmitted during delivery, as well |
|||
* Darkfield microscopy and/or PCR on body fluids, including nasal discharge or CSF |
|||
* Serology |
|||
** RPR on infant blood (not cord blood), paired with maternal RPR |
|||
** May need CSF analysis |
|||
* Also check HIV serology, skeletal survey, chest x-ray, ophthalmology, audiology, and cranial ultrasound |
|||
==Clinical Manifestations== |
|||
== Management == |
|||
* Treat syphilis in pregnancy with high-dose penicillin to prevent congenital syphilis |
|||
* Treat affected infant with [[Is treated by::penicillin G]] 50,000 U/kg/day IV q12h for the first 7 days of life, followed by q8h to complete a total of 10 days |
|||
* Can treat lower-risk infants with [[Is treated by::benzathine penicillin G]] 50,000 U/kg IM once |
|||
*Mothers typically have had no prenatal care |
|||
=== Canadian guidelines === |
|||
*To the fetus, can cause [[Causes::spontaneous abortion]] (40% in untreated primary syphilis), [[Causes::preterm delivery]], [[Causes::polyhydramnios]], [[Causes::intra-uterine growth restriction]], [[Causes::hydrops fetalis]], or [[Causes::intra-uterine fetal demise]] |
|||
* Treat infants at birth if: |
|||
*At birth, two thirds of affected neonates are asymptomatic, with disease developing over the following 6 weeks |
|||
** Symptomatic |
|||
*Early disease, within the first two years, includes: |
|||
** Infant's RPR at least four-fold higher than mother's |
|||
**[[Causes::Rhinitis]] (called [[Causes::snuffles]], often bloody and copious), [[Causes::desquamating rash]], [[Causes::hepatosplenomegaly]], [[Causes::lymphadenopathy]], and skeletal abnormalities |
|||
** Maternal treatment inadequate, did not contain penicillin, is unknown or occurred in the last month of pregnancy, or if the maternal serologic response is inadequate |
|||
**Also: [[Causes::condyloma lata]], [[Causes::vesicular rash]] or [[Causes::bullous rash]], [[Causes::periostitis]], [[Causes::hydrops]], [[Causes::thrombocytopenia]], [[Causes::hepatitis]], [[Causes::jaundice]], or [[Causes::glomerulonephritis]] |
|||
** Adequate follow-up cannt be ensured |
|||
**About 20% involve the CNS |
|||
*Late disease, after the first two years, includes: |
|||
**[[Causes::Sensorineural hearing loss]], [[Causes::intellectual impairment]], [[Causes::saddle nose deformity]], [[Causes::frontal bossing]], jaw, dental, and palatal abnormalities including [[Causes::Hutchison teeth]], [[Causes::saber tibia]], [[Causes::short stature]], and [[Causes::keratitis]] |
|||
==Diagnosis== |
|||
*Darkfield microscopy and/or PCR on body fluids, including nasal discharge or CSF |
|||
*Serology |
|||
**RPR on infant blood (not cord blood), paired with maternal RPR |
|||
**May need CSF analysis |
|||
*Also check HIV serology, skeletal survey, chest x-ray, ophthalmology, audiology, and cranial ultrasound |
|||
==Management== |
|||
*Treat syphilis in pregnancy with high-dose penicillin to prevent congenital syphilis |
|||
*Treat affected infant with [[Is treated by::penicillin G]] 50,000 U/kg/day IV q12h for the first 7 days of life, followed by q8h to complete a total of 10 days |
|||
*Can treat lower-risk infants with [[Is treated by::benzathine penicillin G]] 50,000 U/kg IM once |
|||
===Canadian guidelines=== |
|||
*Treat infants at birth if: |
|||
**Symptomatic |
|||
**Infant's RPR at least four-fold higher than mother's |
|||
**Maternal treatment inadequate, did not contain penicillin, is unknown or occurred in the last month of pregnancy, or if the maternal serologic response is inadequate |
|||
**Adequate follow-up cannt be ensured |
|||
{| class="wikitable sortable" |
{| class="wikitable sortable" |
||
! colspan=3 | |
! colspan="3" |Maternal treatment |
||
! rowspan=2 | |
! rowspan="2" |Neonatal assessment |
||
! colspan=4 | |
! colspan="4" |Recommendations |
||
|- |
|- |
||
! |
!Type |
||
! |
!Timing |
||
! |
!Outcome |
||
! |
!Monthly exam for 3 months |
||
! |
!Serology |
||
! |
!CBC/CSF/x-rays |
||
! |
!Treatment |
||
|- |
|- |
||
| |
|any |
||
| |
|before pregnancy |
||
| |
|adequate, with no RPR rise and no risk factors for reinfection |
||
| |
|normal exam |
||
| |
|no |
||
| |
|no |
||
| |
|no |
||
| |
|none |
||
|- |
|- |
||
| primary, secondary, or early latent |
| rowspan="6" |primary, secondary, or early latent |
||
| |
|>4 weeks before delivery |
||
| |
|adequate |
||
| |
|normal exam, RPR < 4-fold maternal |
||
| |
|yes |
||
| |
|0, 3, 6, and 18 months |
||
| |
|no |
||
| |
|none |
||
|- |
|- |
||
|≤4 weeks before delivery |
|||
| primary, secondary, or early latent |
|||
| |
|||
| ≤4 weeks before delivery |
|||
|normal exam, RPR < 4-fold maternal |
|||
| |
|||
|yes |
|||
| normal exam, RPR < 4-fold maternal |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
|yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
|usually |
|||
| yes |
|||
| usually |
|||
|- |
|- |
||
| |
|||
| primary, secondary, or early latent |
|||
|not penicillin |
|||
| |
|||
|normal exam, RPR < 4-fold maternal |
|||
| not penicillin |
|||
|yes |
|||
| normal exam, RPR < 4-fold maternal |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
|yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
|usually |
|||
| yes |
|||
| usually |
|||
|- |
|- |
||
|before or during pregnancy |
|||
| primary, secondary, or early latent |
|||
|RPR not decline as expected |
|||
| before or during pregnancy |
|||
|normal exam, RPR < 4-fold maternal |
|||
| RPR not decline as expected |
|||
|yes |
|||
| normal exam, RPR < 4-fold maternal |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
|yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
|usually |
|||
| yes |
|||
| usually |
|||
|- |
|- |
||
|before pregnancy |
|||
| primary, secondary, or early latent |
|||
|inadequate, or reinfection |
|||
| before pregnancy |
|||
|normal exam, RPR < 4-fold maternal |
|||
| inadequate, or reinfection |
|||
|yes |
|||
| normal exam, RPR < 4-fold maternal |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
|consider |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
|depends on risk and results of assessments |
|||
| consider |
|||
| depends on risk and results of assessments |
|||
|- |
|- |
||
|during pregnancy |
|||
| primary, secondary, or early latent |
|||
|unknown |
|||
| during pregnancy |
|||
|normal exam, RPR < 4-fold maternal |
|||
| unknown |
|||
|yes |
|||
| normal exam, RPR < 4-fold maternal |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
|consider |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
|depends on risk and results of assessments |
|||
| consider |
|||
| depends on risk and results of assessments |
|||
|- |
|- |
||
| |
|primary or secondary syphilis |
||
| |
|during pregnancy |
||
| |
|inadequate |
||
| |
|normal exam, RPR < 4-fold maternal |
||
| |
|yes |
||
| |
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
||
| |
|yes |
||
| |
|10 days |
||
|- |
|- |
||
| |
|late latent |
||
| |
|during or after pregnancy |
||
| |
|adequate |
||
| |
|normal exam, RPR < 4-fold maternal |
||
| |
|no |
||
| |
|0, 6, and 18 months |
||
| |
|no |
||
| |
|none |
||
|- |
|- |
||
| any |
| rowspan="8" |any |
||
| |
|during pregnancy |
||
| |
|normal exam, RPR < 4-fold maternal |
||
| |
|follow-up unlikely |
||
| |
|yes |
||
| |
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
||
| |
|consider |
||
| |
|depends on risk and results of assessments |
||
|- |
|- |
||
| any |
| rowspan="7" |any |
||
| any |
| rowspan="7" |any |
||
|treponemes on tissue examination |
|||
| any |
|||
|yes |
|||
| treponemes on tissue examination |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
|yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| |
|10 days |
||
| 10 days |
|||
|- |
|- |
||
|infant's RPR four-fold or greater than the mother's at birth |
|||
| any |
|||
|yes |
|||
| any |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| any |
|||
|yes |
|||
| infant's RPR four-fold or greater than the mother's at birth |
|||
| |
|10 days |
||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|- |
||
|four-fold rise in infant's titre |
|||
| any |
|||
|yes |
|||
| any |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| any |
|||
|yes |
|||
| four-fold rise in infant's titre |
|||
| |
|10 days |
||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|- |
||
|signs of congenital syphilis at any age |
|||
| any |
|||
|yes |
|||
| any |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| any |
|||
|yes |
|||
| signs of congenital syphilis at any age |
|||
| |
|10 days |
||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|- |
||
|RPR & TT reactive at 6 months |
|||
| any |
|||
|— |
|||
| any |
|||
|— |
|||
| any |
|||
|yes |
|||
| RPR & TT reactive at 6 months |
|||
|usually |
|||
| — |
|||
| — |
|||
| yes |
|||
| usually |
|||
|- |
|- |
||
|reactive RPR & TT at 12 months |
|||
| any |
|||
|yes |
|||
| any |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| any |
|||
|yes |
|||
| reactive RPR & TT at 12 months |
|||
| |
|10 days |
||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|- |
||
|reactive TT at 18 months |
|||
| any |
|||
|yes |
|||
| any |
|||
|0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| any |
|||
|yes |
|||
| reactive TT at 18 months |
|||
| |
|10 days |
||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|} |
|} |
||
===US guidelines=== |
===US guidelines=== |
||
{| class="wikitable" |
{| class="wikitable" |
||
! colspan=2 | |
! colspan="2" |Initial neonatal assessment |
||
! colspan=2 | |
! colspan="2" |Maternal treatment |
||
! colspan=2 | |
! colspan="2" |Recommendations |
||
|- |
|- |
||
! |
!RPR/VDRL |
||
! |
!Evaluation |
||
! |
!Timing |
||
! |
!Type |
||
! |
!Evaluation |
||
! |
!Treatment |
||
|- |
|- |
||
| rowspan=2 | |
| rowspan="2" |any |
||
| |
|physical exam suggests congenital syphilis |
||
| rowspan=2 | |
| rowspan="2" |any |
||
| rowspan=2 | |
| rowspan="2" |any |
||
| rowspan=2 | |
| rowspan="2" |LP and CBC |
||
| rowspan=2 | |
| rowspan="2" |10 days |
||
|- |
|- |
||
| |
|spirochete in a clinical specimen |
||
|- |
|- |
||
| |
|≥ fourfold maternal titre |
||
| |
|any |
||
| |
|any |
||
| |
|any |
||
| |
|LP and CBC |
||
| |
|10 days |
||
|- |
|- |
||
| rowspan=4 | |
| rowspan="4" |less than fourfold maternal titre |
||
| rowspan=4 | |
| rowspan="4" |normal |
||
| rowspan=2 | |
| rowspan="2" |before pregnancy |
||
| |
|adequate |
||
| |
|none |
||
| |
|none (or one dose) |
||
|- |
|- |
||
| |
|reinfection or relapse (≥4-fold increase in titre) |
||
| |
|LP and CBC |
||
| |
|one dose (unless exam at all abnormal) |
||
|- |
|- |
||
| rowspan=2 | |
| rowspan="2" |during pregnancy |
||
| |
|adequate |
||
| |
|none |
||
| |
|one dose (or none) |
||
|- |
|- |
||
| |
|inadequate or suboptimal |
||
| |
|LP and CBC |
||
| |
|one dose (unless exam at all abnormal) |
||
|- |
|- |
||
| rowspan=2 | |
| rowspan="2" |nonreactive |
||
| rowspan=2 | |
| rowspan="2" |normal |
||
| rowspan=2 | |
| rowspan="2" |during pregnancy |
||
| |
|adequate |
||
| |
|none |
||
| |
|none (or one dose) |
||
|- |
|- |
||
| |
|inadequate or suboptimal |
||
| |
|none |
||
| |
|one dose |
||
|} |
|} |
||
* |
*LP should be sent for VDRL, cell count, protein |
||
* |
*CBC with differential for platelet count |
||
[[Category:Sexually-transmitted infections]] |
[[Category:Sexually-transmitted infections]] |
Revision as of 00:39, 13 August 2020
Background
Epidemiology
- Rare, with about 20 per 100,000 live births in the US
- Greatest risk to child is with untreated primary maternal syphilis
Pathophysiology
- Transplacental transmission while bacteremic
- Can be transmitted during delivery, as well
Clinical Manifestations
- Mothers typically have had no prenatal care
- To the fetus, can cause spontaneous abortion (40% in untreated primary syphilis), preterm delivery, polyhydramnios, intra-uterine growth restriction, hydrops fetalis, or intra-uterine fetal demise
- At birth, two thirds of affected neonates are asymptomatic, with disease developing over the following 6 weeks
- Early disease, within the first two years, includes:
- Rhinitis (called snuffles, often bloody and copious), desquamating rash, hepatosplenomegaly, lymphadenopathy, and skeletal abnormalities
- Also: condyloma lata, vesicular rash or bullous rash, periostitis, hydrops, thrombocytopenia, hepatitis, jaundice, or glomerulonephritis
- About 20% involve the CNS
- Late disease, after the first two years, includes:
- Sensorineural hearing loss, intellectual impairment, saddle nose deformity, frontal bossing, jaw, dental, and palatal abnormalities including Hutchison teeth, saber tibia, short stature, and keratitis
Diagnosis
- Darkfield microscopy and/or PCR on body fluids, including nasal discharge or CSF
- Serology
- RPR on infant blood (not cord blood), paired with maternal RPR
- May need CSF analysis
- Also check HIV serology, skeletal survey, chest x-ray, ophthalmology, audiology, and cranial ultrasound
Management
- Treat syphilis in pregnancy with high-dose penicillin to prevent congenital syphilis
- Treat affected infant with penicillin G 50,000 U/kg/day IV q12h for the first 7 days of life, followed by q8h to complete a total of 10 days
- Can treat lower-risk infants with benzathine penicillin G 50,000 U/kg IM once
Canadian guidelines
- Treat infants at birth if:
- Symptomatic
- Infant's RPR at least four-fold higher than mother's
- Maternal treatment inadequate, did not contain penicillin, is unknown or occurred in the last month of pregnancy, or if the maternal serologic response is inadequate
- Adequate follow-up cannt be ensured
Maternal treatment | Neonatal assessment | Recommendations | |||||
---|---|---|---|---|---|---|---|
Type | Timing | Outcome | Monthly exam for 3 months | Serology | CBC/CSF/x-rays | Treatment | |
any | before pregnancy | adequate, with no RPR rise and no risk factors for reinfection | normal exam | no | no | no | none |
primary, secondary, or early latent | >4 weeks before delivery | adequate | normal exam, RPR < 4-fold maternal | yes | 0, 3, 6, and 18 months | no | none |
≤4 weeks before delivery | normal exam, RPR < 4-fold maternal | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | usually | ||
not penicillin | normal exam, RPR < 4-fold maternal | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | usually | ||
before or during pregnancy | RPR not decline as expected | normal exam, RPR < 4-fold maternal | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | usually | |
before pregnancy | inadequate, or reinfection | normal exam, RPR < 4-fold maternal | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | consider | depends on risk and results of assessments | |
during pregnancy | unknown | normal exam, RPR < 4-fold maternal | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | consider | depends on risk and results of assessments | |
primary or secondary syphilis | during pregnancy | inadequate | normal exam, RPR < 4-fold maternal | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days |
late latent | during or after pregnancy | adequate | normal exam, RPR < 4-fold maternal | no | 0, 6, and 18 months | no | none |
any | during pregnancy | normal exam, RPR < 4-fold maternal | follow-up unlikely | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | consider | depends on risk and results of assessments |
any | any | treponemes on tissue examination | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |
infant's RPR four-fold or greater than the mother's at birth | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
four-fold rise in infant's titre | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
signs of congenital syphilis at any age | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
RPR & TT reactive at 6 months | — | — | yes | usually | |||
reactive RPR & TT at 12 months | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
reactive TT at 18 months | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days |
US guidelines
Initial neonatal assessment | Maternal treatment | Recommendations | |||
---|---|---|---|---|---|
RPR/VDRL | Evaluation | Timing | Type | Evaluation | Treatment |
any | physical exam suggests congenital syphilis | any | any | LP and CBC | 10 days |
spirochete in a clinical specimen | |||||
≥ fourfold maternal titre | any | any | any | LP and CBC | 10 days |
less than fourfold maternal titre | normal | before pregnancy | adequate | none | none (or one dose) |
reinfection or relapse (≥4-fold increase in titre) | LP and CBC | one dose (unless exam at all abnormal) | |||
during pregnancy | adequate | none | one dose (or none) | ||
inadequate or suboptimal | LP and CBC | one dose (unless exam at all abnormal) | |||
nonreactive | normal | during pregnancy | adequate | none | none (or one dose) |
inadequate or suboptimal | none | one dose |
- LP should be sent for VDRL, cell count, protein
- CBC with differential for platelet count